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Methods for phenotype and outcome prediction are largely based on inductive supervised models that 
use selected biomarkers to make predictions, without explicitly considering the functional relationships 
between individuals. We introduce a novel network-based approach named Patient-Net (P-Net) in 
which biomolecular profiles of patients are modeled in a graph-structured space that represents 
gene expression relationships between patients. Then a kernel-based semi-supervised transductive 
algorithm is applied to the graph to explore the overall topology of the graph and to predict the 
phenotype/clinical outcome of patients. Experimental tests involving several publicly available datasets 
of patients afflicted with pancreatic, breast, colon and colorectal cancer show that our proposed 
method is competitive with state-of-the-art supervised and semi-supervised predictive systems. 
Importantly, P-Net also provides interpretable models that can be easily visualized to gain clues about 
the relationships between patients, and to formulate hypotheses about their stratification.
Phenotype and outcome prediction using sets of selected biomarkers are well-established prediction tasks in the 
context of computational biology, including different prediction problems ranging from the response to a specific 
drug1,2, diagnosis and prognosis3–5, classification of cancer subtypes6, outcome and recurrence prediction7–9 and 
other related prediction problems10. State-of-the-art methods for these problems are largely based on inductive 
supervised models that use sets of selected biomarkers, usually represented as vectors, to predict the phenotype or 
outcome of interest (see, e.g.11–13), without taking into account the relationships between individuals.
Several works proposed “network-based” methods by constructing graphs of patients, in order to discover 
the underlying structure of the data (e.g. discovery of subtypes of diseases, clinical stratification of patients)14–17. 
These methods mainly used unsupervised approaches and hence have been not specifically designed and are 
not appropriate for phenotype/outcome prediction problems. Recently a few works proposed semi-supervised 
“network-based” approaches for the prediction of the phenotype/outcome of patients, on the basis of their 
bio-molecular profiles (e.g. gene expression of genotypic profiles)18,19, including also methods able to integrate 
multiple sources of omics data20, and methods based on Supervised Random Walks21, specifically modified for 
the classification of tumors22.
In this work, we introduce a novel network-based method for modeling in the “patient space”. In this context 
the nodes of the network represent patients through an n-dimensional set of biomarker values (e.g. a set of gene 
expression values), and edges represent similarities between the biomarkers of a pair of patients. Hence, this 
“patient-space” differs from the classical “biomarker-space”, where nodes represent biomarkers and edges simi-
larities between biomarkers and not between patients23,24. More precisely, we construct networks of patients on 
the basis of their gene expression similarities (e.g. by considering their expression profiles), and then we apply 
a semi-supervised transductive method to predict their phenotype or clinical outcome. The algorithm leverages 
local learning strategies, by considering the direct neighbors of each node in the “patient network”, as well as 
global topological characteristics of the net through the adoption of appropriate graph-kernels25.
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Our method, that we named P-Net (i.e. Patient-Net), uses the available a priori knowledge about the pheno-
type/outcome of patients and their biomolecular similarity, to assign a score and to rank or to classify patients 
according to the phenotype/outcome under study.
Importantly, P-Net, differently from classical inductive supervised models, is not a mere “black box”, since 
the visual inspection of the network can unravel further characteristics of the patients under study. Indeed, by 
exploiting a cytoscape.js interface, and some rendering options available in the package, it is possible to 
explore and graphically analyze the obtained graph. It is worth noting that P-Net is also completely different from 
semi-supervised network-based methods where genes or proteins represent the main object to be studied24. In 
fact these methods, by exploiting the topological relationships between nodes in gene and protein networks, can 
select markers for specific diseases5,26–32, but cannot be directly applied to predict the outcome or phenotype of 
patients, which is instead the main aim of P-Net.
A large set of experiments with real biomolecular data, including Pancreatic, Breast, Colorectal and Colon 
cancer patients, shows that P-Net is competitive with supervised and semi-supervised state-of-the-art methods 
for phenotype/outcome prediction. A fast and efficient implementation of P-Net is publicly available from GitHub 
(https://github.com/GliozzoJ/P-Net). Moreover, by using a cytoscape.js interface, our method offers an intuitive 
way to explore and graphically analyze the patient network.
Methods
the P-Net algorithm. Network-based ranking of patients with respect to a given phenotype (P-Net) is a 
semi-supervised algorithm able to assign to each patient a score related to its odds to show a specific phenotype 
(e.g. clinical outcome, response to treatment). The predictor is constructed from patients’ molecular profiles 
using a graph G = <V, E>, where the set of vertices V corresponds to patients and the set of edges E to relation-
ships between them (e.g. correlation of expression profiles or correlation of clinical features associated with each 
patient). From this similarity network among patients, a graph kernel (e.g. a random walk kernel) is applied to 
obtain weighted edges aware of the global topology of the network33,34, while edges with low weight are removed 
through a cross-validation procedure. Finally, a scoring system, by exploiting a subset VC ⊂ V of labelled patients 
belonging to the subgroup C of interest (e.g. patients having poor prognosis or responsive to a specific treatment), 
assigns a score to each patient on the basis of the labeling of its neighborhood. The resulting ranking of patients 
can be used to rank or classify them by their likelihood to show a specific C phenotype.
 Figure 1 summarizes the main logical steps of P-Net: 
 1. Data collection and feature selection. The biomolecular profiles of n patients are collected as columns in a 
matrix M. Its m rows refer to the features, e.g. DNA microarray or RNA-seq gene expression measure-
ments, or epigenetic data (Step 1 of Fig. 1). In other words, the columns of M represent the biomolecular 
profiles of patients, while the rows the genomic features associated with each patient. Since usually m 
largely outnumbers n, we apply a feature selection method to reduce the dimensionality and select the most 
relevant features for the phenotype/outcome under study. In our experiments, we used the t-test to select 
the first ranked m m′ <  features available in the training set.
 2. Construction of the patient similarity matrix A matrix W of similarities between biomolecular profiles 
(full biomolecular profiles or signatures) is obtained from the columns (patients) of M (step 2 of Fig. 1). 
To construct W we used the filtered Pearson correlation (by setting to zero all negative values), but other 
measures (e.g. the Spearman correlation or the inverse of some distances, such as the Euclidean or the 
Manhattan distance) can be used instead. We applied filtered Pearson correlation because other correlation 
metrics achieved similar or worse results. W can be seen as the adjacency matrix of the weighted graph G, 
where the edge weights represent the bio-molecular similarity between patients.
 3. Computation of a kernel matrix from the patient similarity matrix The kernel matrix K is derived from 
the similarity matrix W (Fig. 1 - Step 3). This is achieved by choosing a kernel35, able to capture the topolog-
ical characteristics of the underlying graph. Intuitively, the idea is to derive a new graph where there is an 
edge between each pair of nodes that is highly connected (i.e. there exist many short paths between them), in 
the original graph. This means that two nodes may be directly connected in the new graph even if they were 
not in the original graph (see Fig. 2). Several kernels are suitable for this problem (e.g. the diffusion kernel36), 
but for our experiments we chose the random walk kernel37,38, since it showed on average better results: 




2= − + − −
 where I is the identity matrix, D is the “degree” diagonal matrix with elements dii = ∑jwij and a is a value 
larger than 2. A p-step random walk kernel can be obtained by simply multiplying K by itself p times. Intu-
itively, we can think at graph-kernels as functions able to enrich the similarity between nodes in the trans-
formed kernel space, since the novel edge weights of K is determined by the overall topology of the network 
(e.g. novel edges between vertices are added if a path between them of length equal or less than the steps 
of the random walk does exist)39. It is worth noting that a graph kernel implicitly induces a new non linear 
similarity measure between patients, since the novel weights of the computed Gram matrix (i.e. the similar-
ity patient matrix resulting from the application of the kernel) take into account both the topology and the 
metric distance between the nodes/patients to construct a novel “enriched” similarity graph (Fig. 2).
 4. Filtering of the kernel matrix The resulting kernel matrix K is usually very dense, and its sparsification 
is a crucial step that allows to retain only relevant edges, thus reducing the noise introduced by very poor 
similarities between patients. Unfortunately, simply setting an “a priori” threshold, as usually done in other 
experimental contexts33,38,39, leads to poor results. To overcome this problem, we select a threshold τ to 
filter the edges using a very efficient leave-one-out technique that maximizes a pre-selected performance 
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measure (e.g. the Area Under the Receiving Operating Characteristic - AUC) on the training set (see Sec-
tion “Implementation of P-Net” for more details).
 5. Ranking of patients with score functions The score functions associate a score to each node of the network 
on the basis of the labeling of its neighborhood and the weights of its incoming edges (Table 1). SAV, SNN 
and SkNN (Eqs. 1, 2 and 3), derived as described in33,34, compute their score respectively considering the 
average, the nearest and the k nearest labeled neighbours. While these scores exploit only weights coming 
from the labeled neighbours, the remaining score functions STOT, SDiff and SDnorm (Eqs. 4, 5, and 6) allow us 
to exploit the information that comes from the whole neighborhood of the investigated node i, including 
both nodes i ∈ VC and i ∉ VC. In this way the labeling of each node depends on both “positive” and “nega-
tive” annotations of the neighborhood nodes.
Figure 1. Main logical steps of the P-Net algorithm. For simplicity the graph is shown with n = 6 patients. (1) 
Each patient is represented by a vector of m features (e.g. expression levels of the genes). Orange patients have 
the C phenotype; green patients do not show the C phenotype; violet patients are not labelled and our goal is to 
predict their label. We select the m m′ <  features most correlated with the phenotype C and we use them to 
construct a ′ ×m n matrix whose n columns represent the bio-molecular profiles of patients restricted to the m′ 
selected features. (2) A W similarity matrix is constructed, where each element wij represents, e.g., the positive 
filtered Pearson correlation between the patients i and j; note that this matrix can be interpreted as the adjacency 
matrix of the graph of patients. To make the figure readable we show only the entries of patient p2. (3) The 
corresponding K kernel matrix is computed through e.g. 2-step Random Walk Kernel. (4) The K matrix is 
filtered and we remove all the edges with a weight lower than the selected threshold τ = 0.32. (5) A score 
function (e.g. Nearest Neighbour score) is finally used to compute a score for each patient and to rank them 
according to their scores.
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P-Net provides a score to rank patients, but by setting a threshold τ we can obtain a classifier: patients hav-
ing a score larger than τ are classified as positive and the others as negative. In our experiments, we set the 
threshold according to the predicted best accuracy by a fast internal leave-one-out procedure on the training 
set (see Section “Implementation of P-Net”), and then we applied the selected optimal threshold on the test set. 
Additional information about P-Net and its implementation are available in the next Section and in the Section 
“Efficient implementation of P-Net” in the Supplementary Information.
implementation of P-Net. The analysis of the generalization performances of P-Net and the selection of the 
network threshold τ (see “Filtering of the kernel matrix” in the “Methods” Section), can be performed through 
cross-validation or leave-one-out (LOO) procedures. In particular, to obtain an unbiased evaluation of the gen-
eralization performance and an unbiased network filtering, we performed a double leave-one-out procedure: (a) 
an internal LOO to select the network threshold τ; (b) an external LOO to estimate the generalization capabilities 
of the algorithm.
Unfortunately, the classical implementation of the double LOO requires to run the algorithm n2 times, where 
n is the number of patients. To avoid this computational burden, we propose an efficient implementation of the 
P-Net LOO, that requires only a unique run across patients.
Theorem 1: Having a kernel matrix K obtained from the weighted adjacency matrix W of a graph G = <V, E >, 
with vertices v ∈ V denoted with i ∈ { 1, …, |V|}, and N(i) = {j | j ∈ V, kij > 0} the neighbourhood of node i in the graph 
G transformed according to the kernel K, when a leave-one-out procedure is applied with the P-Net algorithm, the 
following fact holds: 
k i is left out0ii = ⇔ .
Figure 2. The graph kernel induces a novel similarity measure between patients. The original network (left side 
of the figure) is constructed using a suitable similarity measure between patients (e.g. the Pearson correlation). 
The p − step random walk kernel “enriches” the original graph by modifying the weights of the original 
network and by possibly adding new edges (coloured in red, graph in the right side): if two nodes are indirectly 
connected through a path of length equal at most to p, a new edge is added between them, and its strength 
depends on the (possible) multiple paths and the weights of the edges along the paths. In other words the graph 
kernel implicitly induces a new non linear similarity measure between patients that takes into account the 
topology of the network and the initial similarity between patients of the original network.
Score Name Formula
Average KS i V k( , , ) (1)AV i C VC j VC ij
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Table 1. Score functions. Elements of K are represented by kij, and its ith row by Ki, while positive integers i, j 
represent nodes (patients); VC ⊂ V represents the set of “positive” patients, i.e. patients associated with the 
phenotype or clinical outcome C of interest.
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Proof:
I. kii = 0 ⇒ node i is left out.
If ∀ i, kii = 0, one of two possible conditions holds:
 1. if i ∉ N(i), kii is not included in the computation of the score function S(i), where S is one of the scores 
functions described in Section “Methods”.
 2. if i ∈ N(i), kii is considered in the score function, but by hypothesis kii = 0
In both cases the score of the node i is computed independently of the labeling of the node i, that is, in other 
words, the node i is left out.
II. kii = 0 ⇐ node i is left out.
If i is left out, even if i ∈ N(i), kii is not used in the computation of the score S. Equivalently we can set kii = 0 and 
then we can use kii in the computation of S(i), since it has no effect on the computation of the score. □
The intuition behind the efficient LOO implementation is that instead of moving away an example/node at 
each round of the LOO procedure and recomputing the score for all the nodes of the network, we can equivalently 
set to zero the self-loop edge of that node. Indeed the information about the labeling of the held-out node i is used 
only in step 5 of the algorithm (see “Ranking of patients with score functions” in the “P-Net algorithm” section), 
and by setting kii = 0 we automatically exclude that node by the computation of its score, i.e. we hold-out that 
node from the training set. As a consequence of the above theorem, to perform the LOO it is sufficient to set to 
0 the diagonal of K and then run one time P-Net across all the nodes of the graph G. For instance, to select the 
optimal threshold τ, we can simply set to zero the diagonal of the kernel matrix K and then apply a unique run 
of P-Net (Fig. 3).
The use of the efficient LOO P-Net procedure for evaluating the generalization performance of the algorithm 
and to select the optimal threshold of the network are described in detail in the Section “Efficient implementation 
of P-Net” in the Supplementary Information.
Accession codes. The datasets from Melanoma, Ovarian, Breast, Colorectal and Colon cancer are all 
available from the Gene Expression Omnibus database (accession numbers GSE53118, GSE26712, GSE2990, 
GSE17536, GSE17538). The Pancreatic cancer dataset is available from ArrayExpress Archive (accession number 
E-MEXP-2780).
Figure 3. A P-Net procedure to find the “optimal” filtering threshold τ.
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Results
We compared P-Net with both supervised inductive methods and semi-supervised network-based algorithms 
for outcome/phenotype prediction. Among supervised inductive methods we selected Support Vector Machines 
(SVMs) and Random Forests since they showed superior performances for these tasks40–42.
We also considered an approach that applies as a first step a network-based method (Net-Rank43), as well 
as other univariate feature selection methods, to select the most relevant features, and as a second step a super-
vised algorithm to predict the outcome using the previously selected features26. Net-Rank enhances the Google 
Pagerank-learning approach44 by using Laplacian regularization and an additive margin: for PageRank the nodes 
are web pages and the edges are hyperlinks between them; for NetRank the vertices of the network are genes and 
the edges are relationships between them (e.g. protein-protein or transcription factor-target interactions). Then 
a Support Vector Machine is trained with the selected features/biomarkers to predict the outcome of patients26.
Finally, we compared our method with an approach developed by Park et al.19. Similarly to P-Net, this method 
applies a semi-supervised learning algorithm on the similarity graph of patients to rank and classify them accord-
ing to a specific phenotype/outcome. However this method differs from P-Net since it adopts a solution in closed 
form to minimize the cost function where both the mislabeling of the patients (the nodes of the graph) and the 
discrepancy between predicted labels of connected nodes in the graph are jointly minimized. Instead, in our 
semi-supervised approach, a graph kernel is firstly applied to capture the overall topological characteristics of the 
graph, and then a score function is applied over the transformed graph to rank patients.
We compared P-Net with each of the above cited methods19,26 by using the same experimental set-up, metrics 
and datasets used by each of them. We also applied the same filtering approach adopted in the first step of the 
P-Net algorithm (i.e. a classical t-test) to select the genes significantly associated with the patients’ phenotype/
outcome, and we performed gene set enrichment analysis45 to uncover pathways and Gene Ontology terms over-
represented in the set of selected genes, to characterize the underlying disease mechanisms.
The data sets used in the experiments are publicly available and are schematically described in the next section.
Datasets description. We applied our novel P-Net method on several microarray gene expression cancer 
data sets.
The Pancreatic ductal adenocarcinoma data set from Winter et al.26 includes 30 patients, split into two groups 
(good prognosis and poor prognosis) according to their survival time (threshold set at 17.5 months, as in the orig-
inal paper26). The Breast, Colorectal and Colon cancer patients were originally analyzed by Park et al.19. Breast 
cancer data are composed of 189 invasive breast cancer patients, divided into the classes “high” and “low” risk 
of recurrence; Colorectal cancer data includes 177 patients and Colon cancer 213, both divided into the groups 
“recurrence”, “no recurrence”. All these data sets include also “unlabeled” patients, i.e. patients having no prog-
nostic or phenotype associated information. Table 2 shows a high-level summary of the data, and further details 
are provided in “Datasets” Section of the Supplementary Information.
Analysis of Breast, Colorectal and Colon cancer patients. Experimental set-up. We compared 
P-Net, using Breast, Colorectal and Colon cancer data, with Park et al. semi-supervised graph-based method 
that minimizes both the classification error and the “internal consistency” of the predicted labeling19. Moreover 
we compared P-Net on the same data sets with three other supervised inductive methods, i.e. SVM, Random 
Forest and Naive Bayes. In the above mentioned experiments we employed the same experimental set-up, based 
on 10-fold cross-validation, as proposed in19. With these data sets P-Net achieved the best results with a Random 
Walk Kernel 1-step and the differential or the differential normalized score function (Table 1). More details about 
the experimental set-up are available in the Section “Experimental set-up for the analysis of Breast, Colorectal and 
Colon cancer patients” in Supplementary Information.
Results. P-Net outperforms the other methods in terms of the Area Under the Receiving Operating 
Characteristic (AUROC) (Fig. 4). Moreover the results are statistically significant, according to the one-tail 
Wilcoxon rank sum test with Bonferroni correction: indeed by applying the statistical test to the repeated 15 
cross-validation we always obtain a p-value lower than 0.01 (Table at the bottom of Fig. 4).
Also, the accuracy and the sensitivity of P-Net are competitive with the other compared algorithms (see 
Table S2 Supplementary Information for more details).
Analysis of Pancreatic ductal adenocarcinoma patients. We compared P-Net with a method that 
applies linear Support Vector Machines trained on biomarkers selected through both a network-based method 
(NetRank) and other simpler univariate feature selection methods26. We did not use non-linear SVMs since in26 
the authors reported that more complex kernels did not lead to better results.
Dataset Accession number Database Labeled patients Unlabeled patients
Pancreatic E-MEXP-2780 ArrayExpress 30 (15 positives) 0
Breast GSE2990 GEO 125 (49 positives) 64
Colorectal GSE17536 GEO 145 (36 positives) 32
Colon GSE17538 GEO 181 (49 positives) 32
Table 2. Summary of all the datasets employed in this work. “Positive” patients are those with poor prognosis or 
high risk of recurrence.
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Experimental set-up. Winter et al.26 used NetRank and a series of univariate feature selection methods: 
fold change, t-statistic, Pearson and Spearman rank correlation coefficients, SAM (Significance Analysis of 
Microarray) method46, and random selection of genes as control, to select the genes most correlated with the 
survival time of a patient. Then the selected top ranked genes were used to train a Support Vector Machine (SVM) 
in order to predict patients with poor (PP) or good (GP) prognosis.
The generalization performances were evaluated through a Monte Carlo cross-validation technique (MCCV). 
More precisely we randomly split the data in training and test set 1000 times. At each round of the splitting 
procedure, we performed feature selection through the t-test using only the data of the training set. Then we 
constructed a network of patients using only the selected genes and we filtered the edges according to the P-Net 
accuracy on the training set by the efficient leave-one-procedure described in the Section “Implementation of 
P-Net”. The score threshold to optimally separate poor and good prognosis patients is computed on the training 
set and the generalization performances are finally evaluated on the separated test. A detailed step by step descrip-
tion of the experimental set-up is available in the Section “Experimental set-up with Pancreatic cancer data” in 
Supplementary Information.
Results. P-Net used the Random Walk Kernel, and the model with p = 8 steps, the Nearest Neighbour score 
function and a set of genes selected according to the t-test achieved the best results. Fig. 5 shows the results (aver-
age accuracy) for a different number of patients in the training set (from 16 to 28). P-Net achieves better results 
than the other methods for each training set size, except with 24 patients, where it obtains the second best result. 
In all cases the difference is statistically significant (t-test at 0.05 significance level). Detailed results showing aver-
age accuracy and standard error of the mean for all assessed methods are available in Table 3.
Figure 4. Comparison of the average AUROC values obtained by P-Net with the Park’s, Random Forest, Naive 
Bayes, and SVM methods over three datasets. AUROC results are averaged across 15 rounds of the 10-fold 
cross-validation. Top: average AUROC with error bars indicating standard deviation (for each dataset, bars are 
sorted according to decreasing performance). Bottom: statistical comparison of P-Net with the other methods. 
P-values are computed by one tail Wilcoxon rank sum test across 15 repetitions of 10-fold cross-validation. 
Rows refer to the methods compared with P-Net; columns to Breast, Colorectal and Colon cancer data.
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Figure 5. Comparison of the accuracy of P-Net and a SVM trained with NetRank and other feature selection 
methods on the Pancreatic cancer dataset. P-Net results are shown in red, SVM with NetRank in cyan, the 
other colors represent the results of the SVM with other feature selection methods (Pearson and Spearman 
correlation, Fold change, t-test), with random selection and with two other variants of the NetRank algorithm 
(Direct Neighbour and Constant c). The x axis reports the number of patients in the training set; y axis reports 
the accuracy.
Training set size 16 18 20 24 28
Method Accuracy (Standard Error of the Mean)
Pearson correlation 56.47% 58.63% 60.82% 65.87% 70.55%
(0.39%) (0.41%) (0.45%) (0.60%) (0.97%)
Spearman correlation 54.57% 55.35% 57.41% 61.20% 68.95%
(0.38%) (0.41%) (0.47%) (0.58%) (1.02%)
Fold Change 47.21% 46.33% 46.27% 44.38% 39.45%
(0.34%) (0.37%) (0.42%) (0.53%) (1.04%)
t-test 54.74% 54.88% 56.00% 58.43% 65.00%
(0.39%) (0.42%) (0.47%) (0.61%) (1.10%)
Random 54.51% 55.38% 56.06% 55.33% 57.25%
(0.40%) (0.40%) (0.46%) (0.58%) (1.08%)
NetRank 62.63% 63.53% 64.60% 68.63% 72.30%
(0.34%) (0.38%) (0.43%) (0.56%) (0.99%)
Direct Neighbour 56.70% 58.73% 61.02% 66.10% 70.55%
(0.39%) (0.41%) (0.46%) (0.60%) (0.97%)
Constant c 63.54% 63.82% 64.34% 65.15% 63.05%
(0.32%) (0.33%) (0.38%) (0.56%) (1.04%)
P-Net 64.23% 64.85% 65.99% 68.03% 78.05%
(2.02%) (2.23%) (2.38%) (3.38%) (7.38%)
Table 3. Comparison of the methods applied to the Pancreatic cancer dataset. The best accuracy value achieved 
for each training set is highlighted in bold.
Figure 6. Comparison of SVM and P-Net after the selection of the top ranked 1000 genes through t-test. The 
vertical bars represent the Standard Error of the Mean (SEM) of the accuracy across 1000 repetitions of the 
hold-out procedure.
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We performed also an additional experiment to understand whether a larger set of biomarkers selected using 
a t-test can enhance the performance of the SVM with respect to P-Net. Results show that, even when selecting a 
relatively large number of biomarkers associated with the poor prognosis (1000 genes), P-Net significantly out-
performs the SVM for any size of the training set (Fig. 6).
In the Section “Summary of P-Net results” in the Supplementary Information we report the detailed results 
obtained by P-Net, including the average AUROC, AUPRC, F1-score and accuracy for each data set. Results show 
that, as expected, P-Net is more stable when relatively large data sets are used.
Assessment of the statistical significance of the patients ranking. For all the considered data sets, 
we applied a non parametric test based on random shuffling of the labels to assess the statistical significance of 
the prediction results47. More precisely we repeat 10000 times a random permutation of the labels, and at each 
iteration of the shuffling we compare the AUC obtained by P-Net with the “true labels” with that obtained with 
the randomly permutated labels. The estimated p-value is the frequency by which the AUC computed with the 
shuffled labels is larger than that computed with the true labels. More details are available in the Section “A non 
parametric test to validate patient ranking” in the Supplementary Information. Table 4 shows that the computed 
p-values are always less than 0.05, confirming that the ranking is not due by chance.
Characterization of genes and pathways involved in patients’ outcome. Linking predictions 
to the underlying disease mechanisms is of paramount importance, and to this end we applied classical gene 
set enrichment analysis to uncover pathways associated with patients’ phenotype and outcome, starting from 
the set of genes selected as differentially expressed at the first step of the P-Net algorithm. We excluded from 
the analysis the pancreatic cancer patients, due to the relatively small number of available examples. More pre-
cisely, we selected the genes significantly associated with phenotype/outcome using the classical t-test with 
Benjamini-Hochberg correction48 at p-value < 0.05 for colorectal and colon cancer and with Bonferroni cor-
rection with p-value < 0.001 for breast cancer. The more restrictive Bonferroni correction is needed to obtain a 
relatively reduced set of differentially expressed genes in breast cancer. We repeated the selection using only genes 
of the training sets across multiple iterations of the 10-fold cross-validation procedure, and we finally selected 
only those genes robustly selected at least 70% of times. Each set of robustly selected genes was further analysed 
using the conditional hypergeometric test to find overrepresented GO:BP terms (p-value < 0.05) and the standard 
hypergeometric test to discover overrepresented KEGG pathways (p-value < 0.05), as implemented in the R pack-
age GOstats45. Since the lists of overrepresented GO terms for breast and colorectal cancer were very large, we 
used REVIGO49, a clustering algorithm based on semantic similarity measures, to obtain a representative subset 
of more interpretable terms.
Additionally, the obtained gene lists were analyzed by Ingenuity Pathway Analysis (IPA, QIAGEN Inc., https://
www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis) software50 (p-value < 0.05) in order to 
further investigate enriched signaling and metabolic pathways related to our selected genes.
Results show that we found genes and pathways known to be associated with breast, colon and colorectal can-
cer, as summarized below. Full lists of the associations, supported by results documented by literature are available 
in Supplementary Information (Tables S3–S8, Fig. S6).
Breast cancer. 364 genes were selected by t-test and used for further functional analysis. Among overrepresented 
KEGG pathways we found “Proteasome” which is a complex dedicated to protein catabolism involved in several 
cellular functions (e.g. regulation of cell cycle, signaling pathways, stress signaling, apoptosis). Recent studies 
suggested that deregulation of the ubiquitin-proteasome pathway may have a permissive role in breast cancer 
development, and drugs which target this pathway are currently in clinical trial51. From our analysis the pathways 
“Protein processing in endoplasmic reticulum” and “Oxidative phosphorylation” resulted overrepresented and 
associated with breast cancer in literature. Endoplasmic reticulum guarantees that only correctly folded proteins 
reach their final destination in the cell while unfolded/misfolded ones are degraded by the proteasome. However, 
endoplasmic reticulum stress (ERS), i.e. the accumulation of unfolded/misfolded proteins in the reticulum, may 
arise due to glucose deficiency, hypoxia, calcium imbalance and oxidative stress. ERS is associated with tumor 
development and metastasis in breast cancer since the high cell proliferation rate in tumors causes hypoxia, 
Dataset P-Net methods p-value (ranking)
Pancreatic - 16 patients RWK8, NN score 0.0010
Pancreatic - 18 patients RWK8, NN score 0.0060
Pancreatic - 20 patients RWK8, NN score 0.0120
Pancreatic - 24 patients RWK8, NN score 0.0060
Pancreatic - 28 patients RWK8, NN score 0.0170
Breast RWK1, Dnorm score 0.0000
Colorectal RWK1, Diff. score 0.0490
Colon RWK1, Diff. score 0.0440
Table 4. Validation of P-Net patients’ ranking using a non parametric test on the different datasets. Results of 
the random label permutation test to assess the significance of patients ranking. RWK stands for Random Walk 
Kernel, Diff. score for Differential score, Dnorm score for Differential normalized score. For the Pancreatic 
cancer dataset, results with different training set sizes are shown.
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nutrients starvation and higher ROS production52,53. In particular, increased ROS production in cancer cells 
arises from oxidative phosphorylation, oxygen metabolism and NADPH oxidase functions leading to oxidative 
stress, described also in breast cancer54.
Considering GO:BP terms, we found some common biological processes known to be involved in tumor 
development, such as “cell cycle phase transition”, “apoptotic signaling pathway” and “signal transduction by p53 
class mediator”. Defects in the cell cycle checkpoints are associated with breast cancer molecular subtypes55 while 
apoptosis escape is one of the hallmarks of cancer56. p53 is a tumor suppressor able to avoid cancer development 
through block of the cell cycle, programmed cell death, repair of damaged DNA and senescence. p53 is mutated 
in 20-30% of breast cancers and it is generally silenced by loss of upstream/downstream mechanisms57. Another 
interesting term is “cellular oxidant detoxification” which is consistent with the presence of oxidative stress in 
breast cancer cells58.
Finally, from IPA analysis mTOR-p70S6K signaling resulted enriched in the Top Canonical Pathways, in 
agreement with its frequent deregulation found in breast cancer, often associated to drug resistance59. The anal-
ysis also revealed that “Cell Death and Survival” and “Cellular Growth and Proliferation” are the molecular and 
cellular functions most significantly overrepresented in the recurrence-associated genes (207 and 139 out of 364 
molecules, respectively). These findings are consistent with GO:BP hypergeometric test and the selected genes 
encoding for cyclins (CCNA2, CCND2), enzymes involved in ubiquitination (UBE2D2, UBE2L3, UBE2N) and 
the transcription factor STAT1. These results are in line with those obtained by other groups which analyzed 
GSE2990 dataset60–62. In particular, Sotiriou and coworkers reported that genes predicting high risk of recurrence 
are mainly involved in cell cycle regulation and proliferation60. Of note, STAT1 was identified as a breast cancer 
recurrence gene also by Park and colleagues62 and it was associated to resistance to endocrine therapy and to 
distant metastasis-free survival by Huang and others61.
Colon and colorectal cancer. A total of 55 genes were found associated with recurrence in colon and colorectal 
cancer. In colon cancer, KEGG pathway analysis highlighted dysregulations in few metabolic pathways, such as 
“Fatty acid biosynthesis”, “Propanoate metabolism” and “Pyruvate metabolism”. Lipid accumulation was observed 
in many cancer types (e.g. brain, breast, ovarian and colorectal cancers), caused by an imbalance between fatty 
acid biosynthesis and β-oxidation, where lipids are used by fast growing cells to support various activities like 
membrane formation and signaling. Abnormal expression of genes involved in fatty acid metabolism was found 
by different studies in correlation with metastasis, drug resistance and relapse63. Notably, many GO:BP terms 
found in our analysis are consistent with aberrant lipid metabolism (“malonyl-CoA biosynthetic process”, “neg-
ative regulation of fatty acid beta-oxidation”, “carnitine shuttle”, “positive regulation of lipid storage”, “negative 
regulation of fatty acid metabolic process”, “regulation of fatty acid oxidation”, “acetyl-CoA metabolic pro-
cess”, “regulation of lipid catabolic process”, “sterol biosynthetic process”, “fatty acid transport”). Considering 
“Propanoate metabolism” and “Pyruvate metabolism”, most tumor cells highly depend on aerobic glycolysis 
rather than mitochondrial oxidative phosphorylation to obtain energy, known as “Warburg effect”, and this dis-
regulates the above mentioned metabolic paths64. Moreover, GO:BP analysis revealed multiple terms related to 
“interleukin mediated signaling pathway” (i.e. IL-2, IL-7, IL-9, IL-12 and IL-15). For instance, Kuniyasu et al.65 
associated the production of IL-15 in colon cancer cells with proliferation, resistance to apoptosis, metastasis and 
angiogenesis.
In colorectal cancer, pathway analysis showed that “Pathogenic Escherichia coli infection” is associated with 
the disease. Indeed, in literature some strains of E. coli are known to produce a genotoxic metabolite (colibactin) 
that alkylates DNA in vivo and contributes to the development and progression of this tumor66. Among biological 
processes consistently overrepresented in our analysis, we found GO:BPs related to the β-catenin destruction 
complex (i.e. “beta-catenin destruction complex disassembly”, “beta-catenin destruction complex assembly”, 
“catenin import to nucleus”), nitric-oxide biosynthesis (“positive regulation of nitric oxide biosynthetic process”, 
“positive regulation of nitric oxide biosynthetic process”, “nitric oxide production involved in inflammatory 
response”), inflammasome (“positive regulation of NLRP3 inflammasome complex assembly”, “pyroptosis”). 
The β-catenin destruction complex was recently found disrupted in colorectal cancer67, possibly enabling the 
migration of β-catenin to the nucleus and the subsequent transcription of target genes. Aberrant stabilization of 
the β-catenin due to mutations in the destruction complex was associated with various cancers68. Regarding the 
biosynthesis of nitric-oxide, colorectal cancer is strongly associated with chronic inflammation and nitric-oxide 
produced by NOS2 is associated with the initiation and progression of the disease. Moreover, over-expression 
of NOS2 is correlated with poor outcome69. Finally, the activation of NLRP3 inflammasome, with consequent 
production of IL-1β, IL-18 and procaspase-1 activation which induces pyroptosis (i.e. a form of programmed cell 
death), showed an anti-tumoral effect preventing/inhibiting colorectal cancer development70.
Functional annotation of selected genes by IPA revealed that 13 out of 54 genes are closely associated to “Cell 
Growth and Proliferation” and “Cell Death and Survival” (AMER1, ATOH7, CSPP1, CTNNB1, DCD, FGF4, 
JAK1, NLRC4, PRF1, SLC29A2, SLC4A1, SP7, TRL4). The top canonical pathways enriched for these genes 
were “Epithelial-Mesenchymal Transition (EMT)”, “Inflammasome” and “iNOS signaling” (see Supplementary 
Fig. S6). Some pathways were detected by both GOstats and IPA. In particular, EMT pathway has been strongly 
associated with the invasive and metastatic phenotype in colon cancer71. Among the deregulated genes involved 
in the EMT signaling, CTNNB1, as well as JAK1 play key roles in colon cancer progression: CTNNB1 through 
the activation of Wnt/β-catenin signaling, and JAK/STAT pathway by regulating cell survival and proliferation, 
differentiation and migration72. Our findings are in line with previous studies showing that CTNNB1 and JAK 
family members are colon cancer recurrence-specific genes and prognostic biomarkers62,72–74. Notably, we also 
identified NLRC4 gene, a member of NOD-like receptors in the “Inflammasome Pathway”, as a novel gene related 
to colon cancer recurrence. Previous studies have shown that NLRC4 takes part in inflammation-induced colon 
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cancer tumorigenesis and participates in anti-apoptotic pathways downstream of p5375. In addition, a recent 
study showed that NLRC4 mediates M2 TAM infiltration and angiogenesis through VEGF production in meta-
static colon cancer76.
Summarizing, the genes and pathways selected in the first step of P-Net, are not only fundamental to achieve 
good phenotype/outcome predictions, but are also related to the biological mechanisms underlying the disease.
Visualization of the P-Net graph. Supervised inductive models in most cases are “black boxes” not suit-
able for interpreting and explaining the obtained results. On the contrary P-Net constructs a graph of patients, 
explicitly showing their biomolecular relationships and embedding at the same time the predicted scores in the 
graph. The graph can be easily shown to the user to provide a visual clue of the relationships between patients 
by means of a graph visualization tool; moreover, the predicted associated phenotype can be properly visualized 
by exploiting a range of colors and shapes. The user is thus enabled to conduct a direct visual inspection of the 
network, which might allow him/her to either uncover hidden relationships/insights about the phenotypic and/or 
biomolecular characteristics of the samples (e.g. disclosing interesting mismatches among similar patients, close 
in the graph, but with different predicted phenotype), or might suggest stratifications of patients on the basis of 
their similarity or predicted phenotype.
As an example of this opportunity, Fig. 7 shows the visual representation of the graph constructed by P-Net 
with the Pancreatic ductal carcinoma data set obtained by adapting to our context a graph visualization tool 
developed in our laboratory for visualizing biomolecular interactions (the tool is detailed in Perlasca et al.77). 
In the figure the patient ground truth is shown by the node shapes (circles for good prognosis patients, and 
rectangles for poor prognosis patients) while the node color shows the prognosis predicted by P-Net. The graph-
ical representation shows that the group of good prognosis patients (highlighted in green) are all correctly pre-
dicted by P-Net. A second group (highlighted by a red ellipse) includes poor prognosis patients predicted by our 
method, some of which are wrongly classified. However, though being labeled as “good prognosis”, the “misclassi-
fied patients” are really borderline patients: their survival time is very close to the cut-off of 17.5 months selected 
in26 to separate good from poor prognosis patients. As another example, Fig. 5 in Supplementary Information 
visualizes the network of Breast cancer patients.
Thus, the graph visualization, eventually coupled with graph clustering algorithms78 and different visualization 
perspectives and interactions, can allow domain experts to identify interesting visual explanations of the achieved 
classification, which would not be so evident in a textual representation of the graph. Different approaches have 
been proposed along this direction, such as77 in the context of biomolecular interactions and79 for the visualiza-
tion of phenotype similarities. These tools offer different functionalities for clustering graph nodes according to 
different similarity measures, for changing the color and the shape of the nodes according to different parame-
ters, for changing the layout perspectives and pointing out different graph properties. All these functionalities 
aid experts to uncover hidden information represented in the graph and to obtain further clues about different 
patients.
Discussion and conclusion
P-Net is a semi-supervised transductive approach where the genetic similarities between patients guide the pro-
cess of outcome prediction and provide a graph representation of the biomolecular similarity between patients. 
P-Net analyses the biomolecular profiles of patients by firstly constructing a similarity graph between them and 
then applying a graph kernel, which extends the notion of similarity between patients and exploits the global 
topology of the graph to discover novel relationships between them. Finally, P-Net ranks patients with respect to 
the phenotype/outcome under study.
Figure 7. Pancreatic cancer graph constructed by P-Net. Square nodes represent “poor prognosis”, while circles 
“good prognosis” patients. The colouring of the nodes is related to the predicted prognosis.
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Our experimental results with different cohorts of cancer patients show that this approach is competitive 
with both network-based and inductive models for outcome prediction. The fast implementation of the P-Net 
leave-one-out procedure, together with the low spatial and time computational complexity of the method (see 
Section “Implementation of P-Net” and Supplementary Information), allow an easy application to actual clinical 
and biomolecular data using off-the-shelf desktop or laptop computers. It is worth noting that by combining 
different kernels and score functions we can obtain different variants of P-Net. From this standpoint P-Net can 
be considered as an algorithmic scheme from which specific learning algorithms can be derived by choosing a 
specific graph kernel and score function.
Several works showed that the outcome results are often not statistically significant and basically due by 
chance80,81. To address this problem, by using a non parametric test based on random shuffling of the labels, 
we showed that P-Net ranking of patients is not due by chance, but on the contrary is significantly related to the 
outcome.
Importantly, P-Net is not only able to predict the phenotype/outcome, but can also construct a graph of 
patients that can be visualized to point out the similarities between their biomolecular profiles and, more in 
general, the relationships between them. In this way we can detect, by visual inspection, closely related patients 
as possible subtypes of a given pathology, or we can identify an incorrect prognosis for a specific patient or for 
possible “outlier patients”. Finally the filtering step of P-Net can be used not only to improve its prediction per-
formance, but also to link predictions to the underlying disease mechanisms, by uncovering genes and pathways 
associated with patients’ outcome/phenotype.
It has been shown that the integration of different kinds of data produces synergies between data that can 
improve the prediction performances82–84. To this end we need at first to construct patient similarity networks 
using similarity measures appropriate for the data at hand. For instance, Pai and Bader for low dimensional 
data (e.g. clinical data) proposed simple measures such as the normalized and average normalized similarity20. 
For patient profiles characterized by a medium size, such as mRNA data, protein expression, miRNA, the same 
authors proposed correlation-based measures (e.g. Spearman, Pearson with and without exponential scaling, 
euclidean or more in general p-norm distances) with or without an initial pre-filtering (using e.g. univariate sta-
tistics or machine learning based feature selection methods). For very high dimensional data (such as genotypic 
or epigenomic data), a pre-filtering step is mandatory to reduce profiles having a very large number of features. 
In this context we can adopt a two-steps pre-filtering, e.g. using a fast univariate feature selection method to drop 
the less significant features and then using a second level multi-variate feature selection method to take into 
account feature interactions and refine the set of selected features (e.g. classical floating search or branch and 
bound methods)85. This framework can be integrated with P-Net by substituting its first two steps (data collection 
and construction of the patient similarity network) with appropriate procedure to construct the network with 
the different data. Then we have two options to accomplish the integration of the different networks: a) direct 
integration from the similarity matrices; b) integration after the application of a graph kernel (step 3 of the P-Net 
algorithm). In both cases we can apply suitable network-based data combination methods, such as simple aver-
aging of the weights of the different networks, or weighted averaging according to the informativeness of each 
source of data20,29,86 or the SNF methods proposed in83. Considering the large range of possible clinical or omics 
data that can be used in this context87, and the different similarity measures and integration techniques that can 
be considered88, we believe that these problems need specific future studies and works that could expand the 
applicability and the effectiveness of the P-Net learning framework.
A limitation of the proposed approach is that P-Net requires potentially expensive feature selection algo-
rithms to reduce the high dimensionality that usually characterizes genomic data, in order to remove irrelevent 
features that could add noise to the network of patients. For computational complexity reasons we applied simple 
univariate methods, but more refined multi-variate methods could lead to better results at the cost of a higher 
computational time complexity89.
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